In a report published Tuesday, Evercore ISI analyst Mark Schoenebaum enumerated the upcoming catalysts for AbbVie Inc ABBV. These include:
- Quarterly calls - Viekira Pak sales in Hep C
- Mid-April 2015 - Phase 2b 12-week RA data JAK1 GLPG0634
- 1H15 - ABT-199 Phase 2 data for del 17p R/R CLL
- 1H15 - ABT-494 Phase 2b data in RA
- 1H15 - Elotuzumab ph3 data in myeloma
- Mid-year 2015 (ISI estimate) - Elagolix 12 month data from phase 3 in endometriosis
- 2H15 - Elagolix Phase 2b data for Uterine Fibroids
- 2H15 - Elagolix 2nd Phase 3 in Endometriosis
- 2H15 - Potential approval in US and EU for Humira in HS
- 2H15 - Completion of Humira phase 3 in uveitis and regulatory submissions
- 2H15 - Potential approval of HCV combo in Japan
- 2H15 - Majority of next-gen HCV (ABT-493/ABT-530) Phase 2b data and initiation of phase 3
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in